The Centers for Medicare & Medicaid Services, or CMS, has initiated a public comment period regarding its intention to continue collecting vital information pertinent to the Medicaid Drug Use Review Program. This move, announced in the Federal Register on August 21, 2026, invites stakeholders and the public to provide feedback on the necessity and efficiency of the existing data collection processes, which are crucial for maintaining patient safety and program integrity within state Medicaid systems. The deadline for submitting comments is October 20, 2026, offering a window for interested parties to influence federal oversight of prescription drug utilization.
The Imperative of Drug Use Review in Medicaid
The Medicaid Drug Use Review program is a cornerstone of federal and state efforts to ensure that Medicaid beneficiaries receive appropriate and safe prescription drug therapies. Established under federal law, the program mandates a proactive and retrospective approach to drug management. Before any prescription is dispensed to a Medicaid patient, a prospective review is required. This critical step involves screening for a range of potential drug therapy problems, including therapeutic duplication, drug-disease contraindications, drug-drug interactions, incorrect dosages or treatment durations, drug-allergy interactions, and instances of clinical abuse or misuse. This front-line defense relies heavily on pharmacists making a reasonable effort to obtain, record, and maintain comprehensive patient profiles. These profiles must document essential patient information such as name, address, telephone number, date of birth or age, gender, medical history including allergies and drug reactions, a list of current medications, and the pharmacist's clinical comments.
Beyond this immediate, point-of-sale scrutiny, the program also mandates retrospective drug use review. This involves an ongoing, periodic examination of claims data and other records. The objective here is to identify patterns indicative of fraud, abuse, or inappropriate and medically unnecessary care. By analyzing these patterns or trends, states can pinpoint recurring drug therapy problems. This data then informs the need for targeted intervention activities involving pharmacists and physicians. These interventions can take various forms, from telephone consultations and correspondence to face-to-face meetings, all aimed at correcting suboptimal practices and enhancing patient outcomes.
Information Collection and Federal Oversight
To monitor compliance and evaluate the ongoing progress and effectiveness of these state-level DUR programs, CMS provides states and managed care organizations with a specific reporting instrument a survey. The responses to this survey form the basis of annual reports submitted to CMS. This federal collection of data is essential for CMS to fulfill its oversight responsibilities, ensuring that federal funds are spent effectively and that Medicaid beneficiaries are protected.
The information gathered through these annual reports is not merely for bureaucratic archiving. CMS reviews these submissions, compiles the results, and publishes a summary comparison of the data on Medicaid.gov annually. This publicly accessible resource serves a broad spectrum of stakeholders. States can utilize the compiled information, including insights into innovative practices reported by other states, to enhance their own DUR programs. The resource also benefits manufacturers, researchers, members of Congress, the Office of Inspector General, non-governmental payers, and clinicians, providing a comprehensive overview of DUR trends and challenges across state Medicaid programs. The current notice specifically concerns the revision of this information collection, identified as CMS-R-153, under OMB control number 0938-0659. The collection occurs yearly, quarterly, and occasionally, affecting 52 state, local, or tribal governments, with an estimated 676 annual responses and a total annual burden of 41,548 hours.
The Significance of Public Comment
Under the Paperwork Reduction Act of 1995, federal agencies are required to seek public comment on proposed information collections, including extensions or revisions of existing ones. This 60-day comment period is a critical mechanism for ensuring transparency, accountability, and efficiency in government operations. It allows the public to scrutinize the necessity and utility of the proposed information collection for the proper performance of the agency's functions. Furthermore, it provides an opportunity to challenge the accuracy of estimated burdens, suggest ways to enhance the quality, utility, and clarity of the collected information, and propose the adoption of automated collection techniques or other forms of information technology to minimize administrative burdens.
For the Medicaid DUR program, public comments could address several areas. Stakeholders might offer insights into the practical challenges states and MCOs face in compiling the required data, suggest refinements to the survey questions to better capture program effectiveness, or highlight technological solutions that could streamline the reporting process. Input from pharmacists, state Medicaid administrators, healthcare providers, and patient advocacy groups is particularly valuable, as their firsthand experiences can illuminate areas where the current information collection might be improved or made more efficient without compromising its core objectives.
Looking Forward
The ongoing need for robust drug use review programs within Medicaid is undeniable, driven by the dual goals of safeguarding patient health and preventing the misuse of public funds. The Centers for Medicare & Medicaid Services' call for public comment on its information collection activities for the Medicaid Drug Use Review Program represents an important opportunity for all involved parties to contribute to the program's effectiveness and efficiency. The insights garnered from this comment period will help shape how CMS monitors and evaluates these crucial state-level initiatives, potentially leading to more refined data collection methods and ultimately, stronger patient protections and more responsible resource allocation in the years ahead. The emphasis on continuous improvement through public engagement underscores the dynamic nature of healthcare regulation and oversight.
